Last reviewed · How we verify
D337
D337 is an investigational drug in phase 3 development by Chong Kun Dang Pharmaceutical with an undisclosed mechanism of action.
At a glance
| Generic name | D337 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available regarding D337's specific molecular mechanism. As a phase 3 candidate from Chong Kun Dang Pharmaceutical, it has progressed through early clinical testing, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases or literature.
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2) (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6) (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348 (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2) (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5) (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg (PHASE1)
- A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391 (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D337 CI brief — competitive landscape report
- D337 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI